RG
ADPT icon

Redmile Group’s Adaptive Biotechnologies ADPT Stock Holding History

Redmile Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-414,400
Closed -$11.5M – 81
2020
Q1 		$11.5M Sell
414,400
-11,300
-3% -$315K 0.32% 52
2019
Q4 		$12.7M Buy
425,700
+1,700
+0.4% +$48.8K 0.3% 55
2019
Q3 		$13.1M Sell
424,000
-1,000
-0.2% -$40.8K 0.44% 50
2019
Q2 		$20.5M Buy
+425,000
New +$18.8M 0.58% 51

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

Redmile Group's ADPT Position: Q2 2020 in Review

Redmile Group sold out of Adaptive Biotechnologies (ADPT) in Q2 2020, closing a stake of 414,400 shares — an estimated $11.5M sold.

Redmile Group first reported a position in ADPT in Q2 2019 and held it in 4 quarters. The position peaked at $20.5M in Q2 2019. 196 funds tracked by Wall St. Rank hold ADPT as of Q2 2020.

  • Redmile Group reported no remaining Adaptive Biotechnologies position as of Q2 2020 after selling out during the quarter.
  • Redmile Group sold 414,400 Adaptive Biotechnologies shares in Q2 2020, an estimated $11.5M.
  • Redmile Group first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 4 quarters.
  • Redmile Group's Adaptive Biotechnologies position peaked at $20.5M in Q2 2019.
  • 196 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2020.

Based on Redmile Group's 13F filing for Q2 2020, filed 14 Aug 2020.